NasdaqCM:ZSAN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology.


Snowflake Analysis

Imperfect balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Zosano Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ZSAN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-12.8%

ZSAN

0.8%

US Medical Equipment

0.5%

US Market


1 Year Return

-50.9%

ZSAN

17.2%

US Medical Equipment

18.7%

US Market

Return vs Industry: ZSAN underperformed the US Medical Equipment industry which returned 17.2% over the past year.

Return vs Market: ZSAN underperformed the US Market which returned 18.7% over the past year.


Shareholder returns

ZSANIndustryMarket
7 Day-12.8%0.8%0.5%
30 Day63.8%5.9%4.9%
90 Day62.6%14.4%19.8%
1 Year-50.9%-50.9%18.1%17.2%21.2%18.7%
3 Year-91.7%-91.7%76.5%71.8%46.2%36.8%
5 Year-99.1%-99.1%130.3%112.4%85.3%65.1%

Price Volatility Vs. Market

How volatile is Zosano Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Zosano Pharma undervalued compared to its fair value and its price relative to the market?

4.22x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ZSAN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ZSAN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ZSAN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: ZSAN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ZSAN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ZSAN is overvalued based on its PB Ratio (4.2x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Zosano Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

52.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZSAN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZSAN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZSAN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ZSAN's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ZSAN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ZSAN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Zosano Pharma performed over the past 5 years?

-8.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ZSAN is currently unprofitable.

Growing Profit Margin: ZSAN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ZSAN is unprofitable, and losses have increased over the past 5 years at a rate of 8.1% per year.

Accelerating Growth: Unable to compare ZSAN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZSAN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.2%).


Return on Equity

High ROE: ZSAN has a negative Return on Equity (-191.65%), as it is currently unprofitable.


Next Steps

Financial Health

How is Zosano Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: ZSAN's short term assets ($11.2M) do not cover its short term liabilities ($16.5M).

Long Term Liabilities: ZSAN's short term assets ($11.2M) do not cover its long term liabilities ($12.7M).


Debt to Equity History and Analysis

Debt Level: ZSAN's debt to equity ratio (8.7%) is considered satisfactory.

Reducing Debt: ZSAN's debt to equity ratio has reduced from 35.8% to 8.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ZSAN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ZSAN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Zosano Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ZSAN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ZSAN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ZSAN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZSAN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ZSAN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Steven Lo (53 yo)

0.83

Tenure

US$874,638

Compensation

Mr. Steven Lo has been Director at Zosano Pharma Corporation since October 2019 and serves as its President and Chief Executive Officer since October 21, 2019. Mr. Lo served as Chief Commercial Officer of ...


CEO Compensation Analysis

Compensation vs Market: Steven's total compensation ($USD874.64K) is above average for companies of similar size in the US market ($USD589.02K).

Compensation vs Earnings: Insufficient data to compare Steven's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Steven Lo
President0.83yrUS$874.64kno data
Donald Kellerman
Vice President of Clinical Development & Medical Affairs5.17yrsUS$420.85k0.0012%
$ 1.1k
Christine Matthews
Chief Financial Officer0.50yrno datano data
Hayley Lewis
Senior Vice President of Operations3.08yrsUS$781.73k0.00035%
$ 333.7
Jeffrey Quillen
Secretaryno datano datano data

2.0yrs

Average Tenure

52.5yo

Average Age

Experienced Management: ZSAN's management team is not considered experienced ( 2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Steven Lo
President0.83yrUS$874.64kno data
Kenneth Greathouse
Independent Director2.83yrsUS$57.90k0.015%
$ 13.9k
Linda Grais
Independent Director1.58yrsUS$96.19kno data
Steven Elms
Independent Director2.25yrsUS$47.90k0.00039%
$ 371.8
Kleanthis G. Xanthopoulos
Independent Director7.33yrsUS$54.89k0.0016%
$ 1.5k
Joseph Hagan
Independent Director5.25yrsUS$57.89kno data
John Walker
Chairman4.25yrsUS$496.05k0.16%
$ 151.5k

2.8yrs

Average Tenure

62yo

Average Age

Experienced Board: ZSAN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 287%.


Top Shareholders

Company Information

Zosano Pharma Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zosano Pharma Corporation
  • Ticker: ZSAN
  • Exchange: NasdaqCM
  • Founded: 2006
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$95.331m
  • Shares outstanding: 68.58m
  • Website: https://www.zosanopharma.com

Number of Employees


Location

  • Zosano Pharma Corporation
  • 34790 Ardentech Court
  • Fremont
  • California
  • 94555
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZSANNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2015
0ZPNDB (Deutsche Boerse AG)YesCommon StockDEEURJan 2015

Biography

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its l ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/14 12:23
End of Day Share Price2020/08/13 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.